Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
>80% KIT knock-down and significant tumor-volume reduction in systemic mastocytosis and GIST models; GLP-validated bio analytics complete; Japan Patent protects through 2039 as IND work advances. Planned Next Steps (Near-Term): — CompleteGLP toxicology and CMC packages; submit IND. — Initiate Phase 1/2 dose-escalation/expansion study in advanced systemicmastocytosis and other KIT-driven tumors with translational biomarkers of […]